The shape-shifting telehealth company has spent the past year trying to cash in on GLP-1s, the hottest drug to hit weight loss in decades. It could all slip away. By Madison Muller and Devin Leonard

The CEO Playbook to Navigating Trump
18:56

The Dawn of Music’s AI Era
32:43

The Startup Making Human Embryos With AI-Assisted Robots
37:40